SAGE Therapeutics to Present at the 2014 Leerink Global Healthcare Conference
SAGE Therapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
SAGE Therapeutics is a neuroscience product focused company developing medicines for critical, orphan and life-threatening specialty central nervous system (CNS) disorders. Our proprietary Positive and Negative Allosteric Modulator (PANAM) platform is driving development of novel allosteric modulators that impact well-validated CNS targets, GABAA and NMDA receptors. SAGE has built a robust product pipeline initially focused on acute and orphan CNS indications, including status epilepticus, anesthesia, and orphan epilepsies, with accelerated development timelines – enabling us to bring important medicines to patients rapidly.